MedTrace Logo

A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI)

NCT01591759 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-04-23

No results posted yet for this study

Summary

This investigation will explore the impact of 8 weeks of citicoline treatment on cognitive function, clinical state and substance use in 40 individuals with mild traumatic brain injury (mTBI).

Conditions

Interventions

DRUG

Citicoline

2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial

DRUG

Placebo

Placebo arm of single-blind study

Sponsors & Collaborators

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • Staci A Gruber, Ph.D. · Mclean Hospital

  • Scott E Lukas, Ph.D. · Mclean Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01591759 on ClinicalTrials.gov